Migration of vascular smooth muscle cells (VSMCs) is a crucial event in atherosclerosis and vascular repair. Low-density lipoprotein (LDL) infiltrated in the vessel wall become aggregated (agLDL) and internalized by VSMC through the LDL receptor-related protein LRP1, deriving in lipid-loaded cells with reduced motility capacity. The urokinase -plasminogen activator (UPA)/UPA receptor (UPAR) system plays a relevant role in vascular remodelling. Here, we investigated whether UPA-ligand binding is involved in the detrimental effects of lipid loading in VSMC migration.
Introduction
Vascular smooth muscle cell (VSMC) migration plays an important role in vascular remodelling in a variety of cardiovascular pathologies including atherosclerosis, in-stent restenosis, and transplant vasculopathy. 1 -3 Migration of VSMC requires properly co-ordinated interaction of cellular and extracellular molecules leading to a sequence of events including cytoskeleton reorganization and cell attachment/detachment, which allow cells to move through the extracellular matrix.
Low-density lipoproteins (LDLs) are the most atherogenic type of lipoproteins both in plasma and in the vessel wall, 4 and retention and aggregation of LDL (agLDL) in the arterial intima, facilitated by the proteoglycans of the extracellular matrix, 5 -7 are key events in atherosclerotic plaque formation. 8 Our group has demonstrated that agLDLs induce high intracellular cholesteryl ester accumulation through LDL receptorrelated protein (LRP-1) uptake in human VSMCs. 9, 10 More recently, we have shown that agLDL impairs VSMC adhesion and migration by inducing changes in cytoskeleton and extracellular matrix protein components. 11 -14 LRP-1 is a large endocytic receptor that binds numerous ligands such as proteases, protease inhibitors, and other plasma membrane proteins, including the urokinase -plasminogen activator (UPA) and its receptor UPAR. 15 Thus, by regulating availability of cell-surface proteins, LRP-1 indirectly controls cell signalling pathways. 16 In addition to its endocytic function, ligand binding to LRP-1 may also directly trigger cell signalling events involved in cell migration and adhesion. 17 UPA is a multi-functional multi-domain protein. Besides its relevant role in fibrinolysis, UPA is also associated with several acute and chronic pathological conditions including vascular disease. 18, 19 Different studies in human and in animal models have suggested that UPA plays a role in the initiation and development of the atherosclerosis 20, 21 Indeed, UPA and its glycosyl-phosphatidyl-inositol anchored receptor UPAR are expressed by VSMCs and macrophages within the atherosclerotic intima. 22 -24 The expression of UPA is up-regulated by molecules directly involved in atherogenesis as platelet-derived growth factor 25 and angiotensin II (Ang II) . 26 In addition, it has been shown that UPA and UPAR are present at increased levels in atherosclerotic human arteries, in proportion to disease severity. 27, 28 Nowadays, however, the overall effects of UPA on plaque composition and stability remain unclear and there is no consensus on the contribution of membrane-bound UPA to the development of atherosclerosis. To this respect, studies in atherosclerosis-prone animals have shown that depletion of UPA promotes progression and instability of atherosclerotic lesions since UPA is required for maintaining cellularity and collagen content in the plaques. 29 In addition, elevated UPA expression in atherosclerotic arteries has been related to intimal growth and constrictive remodelling leading to lumen loss. 21 In contrast, there is experimental evidence supporting a causal connection between elevated lesion uPA expression, disruption of plaque structural integrity, and intraplaque haemorrhage. 30 Beyond the regulation of cell-surface-associated proteolysis, UPA participates in physiological and pathological processes involving cell adhesion, proliferation, and migration. 31 -33 We have previously reported a detrimental effect of atherogenic levels of LDL on UPA/UPARmediated VSMC adhesion and cytoskeleton dynamics. 13 Our goal in the present study was to investigate, whether UPA acting as a ligand to UPAR could also regulate the detrimental effects of atherogenic LDL on VSMC migration capacity, and whether LRP1, major receptor for internalization of atherogenic agLDL, is required in the process.
Materials
See Supplementary material online for expanded methods.
Animals
Seven-week old Sprague -Dawley rats were fed a western type high-fat (HF) diet to induce hypercholesterolaemia or a regular diet for 14 days (n ¼ 10 animals/group). On Day 1, rats were implanted with subcutaneous osmotic mini-pumps. During the 2-week period, 50% of the animals in each diet group (hyperlipaemic and normolipaemic) were infused at 200 ng/kg per min with Ang II and 50% saline solution, as previously described. 34 On Day 14, animals were euthanized, aortas dissected, and cleaned of fatty tissue, opened longitudinally and the endothelial layer gently removed. Afterwards, aortas were dissected in segments that were used for in vitro migration studies and analysis of protein expression. Representative segments along the aorta were chosen for each of the tested variables. Serum lipid profile was analysed in all animals (see Table 1 ). All procedures fulfilled the criteria established by the 'Guide for the Care and Use of Laboratory Animals' and were approved by the Internal Animal Committee Review Board.
Cell migration assay from aorta explants
From each animal, 20 thoracic-aortic segments (1×1 mm) were placed with the luminal side down onto tissue culture plates and maintained in M199 medium (Gibco) containing 10% foetal bovine serum (FBS; Biological Industries), 100 U/mL penicillin (Gibco), 100 mg/mL streptomycin (Gibco), and 2 mmol L-glutamine (Gibco) at 378C in a 95% air-5% CO 2 humidified atmosphere. Medium was replaced every 2 days and the number of explants showing rat vascular smooth muscle cell (RVSMC) migration was recorded daily over a period of 6 days.
Human VSMC culture and LDL preparation
Primary human VSMCs were cultured in M199 medium containing 20% FBS, as previously described. 13 Except when indicated, experiments were made in subconfluent monolayer of control and LDL-loaded VSMC after incubation with agLDL (100 mg/mL) for 16 h. VSMCs were incubated with 1 mM Ang II to enhance UPA expression during exposure to agLDL as previously described 13 or treated with 2 mg/mL human exogenous UPA. In specific subsets of experiments, UPA function and ligand-binding capacity were blocked with specific polyclonal (anti-UPA) or monoclonal (anti-UPA ATF) antibodies and the UPA expression was silenced with a commercial specific siRNA using the Human AoSMC Nucleofector kit (Amaxa). Suppression of UPA expression was proved by real-time-PCR and western blot analysis ( Figure 3C and D). Human LDLs (density 1.019-1.063 g/mL) were prepared by ultracentrifugation from pooled sera of normocholesterolaemic volunteers and agLDL were generated by vortexing LDL (1 mg/mL), as previously described. 10 
In vitro wound repair assay
A double-sided scrape wound was made on confluent VSMC monolayer, as previously described. 4 Cell migration and wound repair were analysed on 10% FBS-stimulated cells using an inverted microscope and a video SPOT camera. Images were taken on four different fields along the linear scratch, covering in total .95% of the initial celldepleted area. Cell migration and wound repair were quantitatively assessed using Rasband, National Institute of Health) by measuring the residual celldenuded area at the different time periods between 0 and 10 h.
mRNA and protein extraction
Rat aortic tissue extracts were prepared using Tripure isolation reagent (Roche) after tissue homogenization of representative apparently normal segments taken along the aorta of each animal (n ¼ 4/group). Human VSMC mRNA and protein extracts were prepared from migrating and growth-arrested cells using RNeasy Mini Kit (Qiagen) and RIPA buffer for extraction of mRNA and proteins, respectively.
2.6 Real-time PCR, western blot, and confocal microscopy analysis mRNA and protein expression were analysed by real-time PCR and western blot, respectively. Immunofluorescence and confocal microscopy were used in studies of cellular protein localization. All procedures were performed as previously described. 13 
Statistical analysis
Results are presented as mean + SEM and the number of experiments is shown in every case (see figure legends). Statistical differences between groups were analysed by the non-parametric tests (Kruskal-Wallis, Mann-Whitney) or by the parametric test one-way analysis of variance (ANOVA) followed by the Bonferroni or the Fisher's PLSD test for group differences. Statistical significance was considered for P values of 0.05 or less.
Results

Hypercholesterolaemia impairs RVSMC outgrowth from aorta
Animals fed with an HF diet for 14 days showed a significant increase in plasma total cholesterol (HF group: 216.8 + 33.7 mg/dL vs. control group: 100.1 + 3.53 mg/dL, P , 0.05; Table 1 ) and five-fold higher cholesterol-LDL levels than those animals receiving a regular chow (HF group: 87 + 929.9 mg/dL vs. control group: 17.8 + 0.6 mg/dL, P , 0.05; Table 1 ). Using an ex vivo model of aortic-tissue culture, we analysed the frequency of aortic explant outgrowth, RVSMC migrated from 15/20 of the aortic segments cultured from animals fed with the regular chow, whereas RVSMC migration from animals fed with the HF diet was only observed in 7/20 of the aortic segments cultured during a 6-days period (P , 0.05, Figure 1A and B). In vivo administration of Ang II (200 ng/kg/day) during 14 days significantly accelerated the rate of RVSMC migration from the aortic explants ( Figure 1C) . Indeed, RVSMC derived from the groups receiving Ang II (control + Ang II and HF + Ang II) started to migrate from the aortic explants after 3 days in culture, whereas RVSMC migration from animals that did not receive Ang II was first detected after 4 days in culture. While Ang II significantly increased the rate of RVSMC outgrowth from the aortic segments, it did not affect significantly the frequency of outgrowth (number of explants showing RVSMC outgrowth), neither in the HF nor in the control group.
Hypercholesterolaemia reduced over 50% UPA-antigen levels in aortic tissue (P , 0.05) ( Figure 1D ), while Ang II induced a significant increase in UPA-aortic levels (P , 0.05) ( Figure 1D ).
agLDL decreases UPA mRNA and protein expression in migrating VSMC
To investigate the mechanism by which high lipid levels decrease VSMC migration capacity, we performed studies on human VSMC exposed to atherogenic concentrations of agLDL. UPA mRNA and protein expression was significantly decreased in the presence of agLDL in migrating VSMCs, this effect being prevented by Ang II (Figure 2A and B) . However, Ang II alone (in the absence of agLDL) did not show any significant effect on UPA expression, neither at the mRNA nor at the protein level, in migrating human VSMCs ( Figure 2C ). LRP-1 mRNA expression was significantly increased by agLDL in migrating VSMC either in the absence or presence of Ang II. In contrast, no effects were observed in the expression of the mRNA UPA receptor, UPAR, under similar conditions (Figure 2A) . In growth-arrested VSMC, UPA mRNA levels were not reduced by agLDL, whereas LRP-1 mRNA levels were significantly increased ( Figure 2D ). Changes in UPA-and UPAR-protein levels showed similar trend ( Figure 2E ).
3.3 UPA controls cell migration and wound repair in VSMC exposed to agLDL UPA plays a pivotal role during lipid-loaded VSMC migration. As shown in Figure 3A and B, exogenously added UPA (2 mg/mL) or Ang II treatment (1 mM, UPA endogenously induced) restored to control levels the wound repair capacity of agLDL-loaded VSMC. Neither exogenous UPA nor Ang II affect wound repair capacity of control VSMC, not exposed to agLDL UPA/UPAR system and lipid-loaded VSMC migration Down-regulation of UPA expression by gene silencing (Figure 3C and D) significantly reduced VSMC migration when compared with the random siRNA-transfected control cells ( Figure 3E ). agLDL did not affect wound repair kinetics in UPA-silenced VSMC and wound repair capacity of UPA-silenced VSMC did not differ significantly from that of random siRNA-transfected-VSMC exposed to agLDL (42.6% + 2.8 agLDL vs. 45.3% + 3.1, respectively; Figure 3E ). In contrast to the Ang II effect in agLDL-VSMC transfected with random siRNA, Ang II did not restore cell migration capacity in agLDL-VSMC with downregulated UPA mRNA expression ( Figure 3E) .
In rescue experiments, addition of 2 mg/mL exogenous UPA to UPAsilenced VSMC cells restored kinetics of wound repair to the level of the control VSMC (random siRNA-tranfected control cells), independently of the presence or absence of agLDL ( Figure 3E) .
We have previously demonstrated that agLDL-induced impairment of VSMC repair function is reversed by the HMG-CoA reductase inhibitor, rosuvastatin. 12 Here, blockade of UPA function and ligand-binding capacity, with a specific polyclonal antibody (anti-UPA, 40 mg/mL), significantly reduced the increase in percentage of wound coverage induced by rosuvastatin (10 mM) in agLDL-VSMC (P , 0.05; Figure 4A ). In addition, treatment of agLDL-VSMC with 10 mM rosuvastatin restored the UPA mRNA and protein expression levels to those in control VSMC (control group, Figure 4B and C ).
agLDL induces UPA subcellular delocalization without affecting UPAR distribution in migrating VSMC
The effect of agLDL on the subcellular distribution of UPA and its receptor UPAR was analysed by confocal microscopy. Strong UPA fluorescence signal (green signal) was consistently detected at the front edge of control migrating VSMC (Figure 5Aa and Ab), whereas only a weak UPA labelling was evident at the front edge of the agLDL-loaded VSMC, located at the border of the wounded area (Figure 5Ac and Ad). Ang II increased UPA labelling at the front edge of agLDL-VSMC to the level of controls (compare Figure 5Ae and Af with Ac and Ad, respectively). agLDL did not affect the intensity and cell distribution of UPA in nonmigrating VSMC (see Supplementary material online, Figure S1 ). UPAR showed a diffuse labelling pattern all over the cell, without any particular distribution (Figure 5Ag and h ). agLDL and Ang II did not influence UPAR localization in the migrating VSMC (compared Figure 5Ag ,h with 5Ai-j and 5Ak-l).
UPA-induced cell migration on agLDL-VSMC is dependent on UPAR-binding
To further investigate whether the effect of UPA on the migration capacity of lipid-loaded VSMC was mediated by UPA acting as ligand of UPAR, we performed a set of experiments using a monoclonal antibody against the amino-terminal fragment (ATF) of UPA (anti-UPA ATF, 40 mg/mL) that interferes in UPA-UPAR binding. As shown in Figure 5B , 8 h after injury the two-fold increase in the % of wound coverage induced by UPA in agLDL-VSMC was totally abrogated by anti-UPA ATF.
In addition, quantitative analysis of colocalization between UPA-and UPAR-fluorescent labelling signals (confocal microscopy under nonpermeabilized conditions, Figure 5C and see Supplementary material online, Figure S2 ), over an area of 12 mm of the front edge of migration, demonstrated a significant decrease in colocalization density from 31.7 + 1.4% in control cells (yellow signal in Figure 5Ca ) to 23.0 + 1.4% (yellow signal in Figure 5Cb ) in agLDL-treated cells.
3.6 LRP-1 and UPA-mediated migration in lipid-loaded VSMC LRP-1 has been shown to regulate the biological functions of several ligands. To test whether UPA effects on agLDL-VSMC involve LRP-1, we pre-treated VSMC with RAP, a well-established LRP-1 antagonist that neutralizes the binding to LRP-1 of different ligands including UPAR. As shown in Figure 6A , 200 nM RAP significantly reduced wound coverage in exogenous UPA-treated agLDL-VSMC. The same response was observed in parallel experiments when cells were treated with Ang II to enhance endogenous UPA expression. The magnitude of the decrease in cell migration did not differ statistically between agLDL-VSMC incubated with 1 mM Ang II and those treated with 2 mg/ mL exogenous UPA.
To proof the specificity of RAP effects on a UPA-dependent mechanism, we performed a set of experiments where the effect of RAP was investigated in cells previously treated with a polyclonal antibody against UPA (anti-UPA) to fully block the UPA function and ligand capacity, or with monoclonal antibody directed to the UPA ATF (anti-UPA ATF) to inhibit the binding of UPA to UPAR without affecting UPA-proteolytic domain. As shown in Figure 6B UPA/UPAR system and lipid-loaded VSMC migration VSMC were incubated with RAP before adding the anti-UPA or the anti-UPA ATF antibodies, data not shown).
Given the observed LRP-1-dependent UPA effects on migration of agLDL-VSMC, potential changes on cell-surface distribution of LRP1 were next characterized by confocal microscopy. As shown in Figure 6D , LRP-1 depicted a patched distribution in migrating VSMC, only focally detected at the leading edge of the migrating cells (arrow head in Figure 6Da ). LRP-1 was increased on the surface of agLDL-treated cells, but with weaker or no detection at the front edge of cells located at the wound border (Figure 6Db) . The presence of exogenous UPA decreased LRP-1 labelling on cell surface of agLDL-VSMC, turning into an LRP-1 pattern distribution similar to this in control VSMC with Figure 5 Effect of agLDL on UPA-and UPAR localization at the leading edge of migrating cells. Confocal microscopy for UPA-and UPAR antigen in migrating human VSMC. (A) Representative photomicrographs of UPA or UPAR labelling (green signal) in permeabilized (5Aa,c,e and 5Ag,i,k) and nonpermeabilized (5Ab,d,f and 5Ah,j,l) migrating cells at 4 h after wounding. In red: F-actin stained with phalloidine. (B) Bar diagram for wound coverage by agLDL-VSMC (100 mg/mL agLDL) treated with/without exogenous UPA (2 mg/mL) in the presence/absence of a monoclonal antibody against ATF domain of UPA (anti-UPA-ATF, 40 mg/mL) at 8 h after wounding. Results: mean + SEM (n ¼ 3 independent experiments). P , 0.05 (ANOVA/Fisher's PLSD test): anti-UPA-ATF groups vs. *control VSMC (2agLDL/2exogenous UPA); † vs. agLDL-VSMC (+agLDL/+exogenous UPA). (C) Representative photomicrographs for UPA/UPAR colocalization on cell surface (non-permeabilized conditions) of control-and agLDL-VSMC during cell migration (4 h after wounding). Merge images: UPA (green), UPAR (red), colocalization (yellow). UPA/UPAR colocalization was calculated over an area (12 mm UPA/UPAR system and lipid-loaded VSMC migration focused detection at the front cell border (arrow head in Figure 6Dc ). Adding RAP into the culture medium abrogated the effect induced by exogenous UPA on LRP-1 localization at cell surface of the lipid-loaded VSMC (Figure 6Dd) . In these cells, LRP-1 showed a similar distribution to that observed in agLDL-VSMC located at the border of the wound. A similar LRP-1 patched distribution with less evidence of difference between groups was found on permeabilized VSMC (Figure 6De-h ).
Discussion
The UPA/UPAR system is considered to be a key regulator of tissue remodelling, being implicated in a broad spectrum of (patho)physiological processes directly involved in atherosclerosis such as cell adhesion and migration and matrix turnover. 13, 20, 31, 32, 35 UPA and its receptor UPAR are strongly expressed in human atherosclerotic lesions 20, 23, 27 and local UPA expression levels in human coronary arteries have been reported to correlate with the severity of the disease. 23, 27 Some lines of evidence, based on atherosclerosis animal models, appear to support that UPA overexpression contributes to progression of atherosclerosis due to arterial constriction and lumen loss, 21 but also to the stability of atherosclerotic plaques by maintaining cellularity and collagen content. 29 As previously described, LDL infiltrated in the vessel wall become aggregated and retained in the intima by proteoglycans.
5,7 VSMC internalize agLDL through the endocytic receptor LRP-1 9,10 deriving in lipid-loaded cells with impaired cytoskeleton dynamics and reduced adhesion and migration capacity, 4, 12 mechanisms that could contribute to the relative loss of human VSMC in the vulnerable plaques.
Here, we were interested in understanding whether elevated LDL plasma levels can affect the phenotype and function of VSMC and more specifically their migration capacity in a pre-atherosclerotic state. Using a model of coronary atherosclerosis in mini pigs, it was previously shown that hypercholesterolaemia impairs vascular remodelling of balloon-treated coronary arteries and decreases VSMC and collagen accumulation at the site of injury. 36 Here, using a HF diet rat model, we now extend these previous results reporting that hypercholesterolaemia impairs VSMC capacity to migrate from aortic explants and decreases UPA levels. The observation that UPA up-regulation by using Ang II 13 was linked to an accelerated VSMC outgrowth from aortic explants of apparently normal arterial tissue provides insight into the relevance of UPA on VSMC migration. Our recent findings revealed that the inhibitory effect of atherogenic levels of lipids on cytoskeleton dynamics and cell adhesion is linked to alterations of the UPA/ UPAR system. 13 Here, we report for the first time that UPA-ligand binding is involved in the detrimental effects of high lipid levels on human VSMC motility. Human VSMCs exposed to atherogenic concentrations of agLDL expressed low levels of UPA and depicted changes in its subcellular localization during cell migration, without showing any evident change in the level or localization of the receptor UPAR. In fact, UPAwas strongly polarized at the leading edge of migrating cells not exposed to lipids, whereas agLDL-loaded cells showed reduced UPA signalling at the front migration edge. Interestingly, the effect of agLDL on UPA was observed in migrating VSMC but not in quiescent cells. In growth-arrested cells UPA gene and protein levels, as well as its subcellular distribution, were unaltered.
Exogenous UPA restored wound repair capacity of human lipid-loaded cells to the level of the control group. Noteworthy, our results demonstrated that exogenous-added or endogenous-induced UPA does not affect VSMC migration in the absence of agLDL. These results demonstrate that the impairing effects of agLDL on VSMC migration are mediated by UPA. In addition, we have shown that agLDL did not affect wound repair kinetics in UPA-silenced cells, suggesting that the residual VSMC migration observed in the presence of agLDL is independent of the UPA pathway. The decrease of cell migration due to UPA silencing was restored in the presence of exogenous UPA both in control cells and in agLDL-loaded cells, whereas, treatment with Ang II was not able to normalize migration in agLDL-VSMC with silenced UPA expression. The fact that rosuvastatin, a potent statin that has shown to induce stabilization of vascular lesions, 37 and regression of clinical coronary atherosclerosis 38 rescues migration and repair capacity of lipid-loaded VSMC through a UPA-dependent mechanism, open novel therapeutic perspectives in the prevention of plaque rupture, and cardiovascular outcomes by strategies directed to restore fully functional VSMC. UPA acts both as serine protease and signalling ligand by UPARdependent and UPAR-independent pathways. 25, 33, 39 Here, we have
shown that blockade of UPA-UPAR interaction, with specific antibodies, significantly abolished the exogenous UPA-induced recovery of cell migration in lipid-loaded cells, suggesting a mechanism mediated by UPA-UPAR binding. Our findings are supported by the observation that the presence of agLDL significantly decreased colocalization of UPA with UPAR at the leading edge area. UPAR lacks an intracellular domain; therefore, the response to UPA binding requires the formation of multi-protein complexes with other adaptor proteins, including LRP-1 16 to trigger intracellular signalling.
Here, by neutralizing ligand binding to LRP1 with RAP, the effects of exogenous UPA and Ang II on agLDL-VSMC migration were significantly abolished. LRP-1 is an endocytic and cell-signalling receptor for diverse ligands with a potential role in cell migration 40, 41 and RAP has been reported to interfere with binding of large number of ligands to LRP1. 42 In this study, we provide evidence that RAP does not elicit any effect on cell migration when the UPA function and ligand-binding capacity to UPAR were previously blocked with specific antibodies. These findings strongly emphasize the requirement of UPA/UPAR-LRP1 association for the observed effect of UPA restoring wound repair capacity of lipid-loaded VSMC. Although the effects of LRP-1 on uPA internalization and signalling have been examined in different systems, 16 this is the first study showing a linked contribution of LRP-1 and UPA to trigger lipid-loaded VSMC migration. To this respect, UPA facilitates cell-surface localization of LRP1 in focal clusters at the front edge of migrating lipid-loaded VSMC, a distribution pattern characteristic of migrating control VSMC that seems to require the interaction UPA/UPAR-LRP1, as suggested by inhibition studies with RAP. Taken together these results, LRP-1 emerges as a receptor that mediates UPA-dependent lipid-loaded VSMC migration, a characteristic phenotype in atherosclerotic lesions. Our results, however, do not rule out the existence of co-receptors that may function with LRP-1 to mediate migration of lipid-loaded VSMC in response to UPA.
In summary, the ability of atherogenic lipids to interfere the UPA/ UPAR-dependent VSMC migration is a novel observation as it is the finding that regulation of UPA restores the migration capacity of VSMC exposed to aggregated LDL levels through an LRP-1-mediated mechanism. These results support the view that tissue infiltrated LDL through the abrogation of UPA function reduces VSMC-regulated vascular repair and contribute to the progression of atherosclerotic lesions. Future investigation should focus on identifying target molecules involved in the process to open therapeutic perspectives in the prevention of plaque rupture and cardiovascular outcomes.
